Collegium To Report Third Quarter 2026 Financial Results On November 5, 2026
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the“Collegium Pharmaceutical Q3 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company's website: . The webcast will be available for replay on the Company's website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM®(methylphenidate HCl) CII and AZSTARYS®(serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.
For more information, please visit collegiumpharma.com or find us on LinkedIn.
Investor Contacts:
Ian Karp
Head of Investor Relations
...
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment